Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2001 Apr;124(1):157–162. doi: 10.1046/j.1365-2249.2001.01503.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2001 Blackwell Science Ltd

PMC Copyright notice

Fig. 1 — In their pharmacological range, dapsone or nicotinamide do not reduce cell viability of NHEK. NHEK were stimulated with 4 mg/ml IgG from a BP patient (BP IgG), IgG from a healthy volunteer (Normal IgG), and with medium alone (Medium). In addition, 4 mg/ml normal human IgG was incubated with various concentrations of dapsone or nicotinamide (pharmacological ranges are indicated with †) for 12 h. Cell viability was analysed by a nonradioactive cell proliferation assay. Samples were tested in duplicate, bars show mean ±SD. *statistical significant difference in cell viability compared to normal IgG-treated NHEK (P < 0·01). □ BP IgG; Normal IgG; ▪ Medium.

Inline graphic — In their pharmacological range, dapsone or nicotinamide do not reduce cell viability of NHEK. NHEK were stimulated with 4 mg/ml IgG from a BP patient (BP IgG), IgG from a healthy volunteer (Normal IgG), and with medium alone (Medium). In addition, 4 mg/ml normal human IgG was incubated with various concentrations of dapsone or nicotinamide (pharmacological ranges are indicated with †) for 12 h. Cell viability was analysed by a nonradioactive cell proliferation assay. Samples were tested in duplicate, bars show mean ±SD. *statistical significant difference in cell viability compared to normal IgG-treated NHEK (P < 0·01). □ BP IgG; Normal IgG; ▪ Medium.